EMBIOSYS INC.

Medtech · Private

Wearable garment device delivering induced electric field (iEF) therapy for triple-negative breast cancer treatment

Grants
$1.8M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development Of A Wearable, Non-invasive, Treatment Device For Metastatic Triple-negative Breast Cancer (tnbc)$211,125
Federal grantDepartment of Health and Human Services · Phase I · Development Of A Wearable, Non-invasive, Treatment Device For Metastatic Triple-negative Breast Cancer (tnbc)$188,875
Federal grantDepartment of Health and Human Services · Phase II · CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer$1,379,442
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2033FLEX ORTHOPAEDICS, INC.——
2034SONOVANCE, INC.——
2035ENDOTAT BIOTECHNOLOGIES LLC——
2036EMBIOSYS INC.——
2037OLMEDA BIOSCIENCES LLC——
2038AIMLOXY LLC——
2039PERSISTENCE THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.